

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Alfieri Ottavio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Valtech : Mitral products (2011)</li> <li>- Edwards Lifesciences : Prosthetic rings (2011)</li> <li>- Symetis SA : Transapical aortic prosthesis (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Valtech : Mitral rings (2010)</li> <li>- Symetis SA : Transcatheter aortic valve (2010)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Mitral rings (2010)</li> </ul>
Andreotti Felicita	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Anticoagulant agent (2010)</li> <li>- Bristol Myers Squibb : Anticoagulant agent (2010)</li> <li>- Astra Zeneca : Antiplatelet agent (2010)</li> <li>- Daiichi Sankyo : Antiplatelet agent (2010)</li> <li>- Eli Lilly : Antiplatelet agent (2010)</li> <li>- Bayer Healthcare : Antiplatelet agent; Anticoagulant agent (2010)</li> <li>- Bayer Schering Pharma : Aspirin, rivaroxaban (2011)</li> <li>- BMS-Pfizer : Apixaban, cardiovascular metabolism (2011)</li> <li>- Pfizer (see also BMS) : Apixaban (2011)</li> <li>- Daiichi Sankyo : Edoxaban (2011)</li> <li>- Eli Lilly : Prasugrel (2011)</li> </ul>
Antunes Manuel J	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Occasional activity - Mitral valve repair- Carpentier Edwards ring (2011)</li> <li>- Edwards Lifesciences : Occasional speaker fees / expenses (2010)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- St Jude Medical : Occasional speaker fees / expenses (2010)</li> </ul>
Baron Esquivias Gonzalo	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Bayer : Anticoagulation (2010-2011)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2010-2011)</li> <li>- Bristol Myers Squibb : Anticoagulation (2010)</li> <li>- Rovi : Dislipidemia (2011)</li> </ul>
Baumgartner Helmut	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2010-2011)</li> <li>- AGA : Devices for catheter treatment of congenital heart defects (2010)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2011)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2010)</li> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2011)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2011)</li> </ul>
Borger Michael A	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Edwards Lifesciences : heart valve therapy (2010-2011)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- St Jude Medical : heart valve therapy (2010)</li> <li>- St Jude Medical : heart valve therapy (2011)</li> <li>C - Receipt of royalties for intellectual property.</li> <li>- Medtronic : heart valve therapy (2010)</li> <li>- Medtronic : heart valve therapy (2011)</li> </ul>
Carrel Thierry	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- ATS : Heart Valves (2010)</li> <li>- Edwards Lifesciences : Heart Valves (2011)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : Heart Valves (2010)</li> <li>- Medtronic : Heart Valves (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- ATS : Heart Valves (2010)</li> <li>- Medtronic : Heart Valves (2010)</li> <li>- St Jude Medical : Heart Valves (2010)</li> <li>- Medtronic : Heart Valves, Endovascular Stent-Grafts (2011)</li> <li>- Edwards Lifesciences : Heart Valves (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sorin Group : Heart Valves (2010)</li> <li>- St Jude Medical : Anticoagulation (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2011)</li> </ul>
De Bonis Michele	<ul style="list-style-type: none"> <li>- Nadirex International srl : Ventricular Assist Devices (2011)</li> </ul>
Evangelista Masip Artur	None
Falk Volkmar	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Valtech : minimally invasive mitral valve surgery (adjustable rings, chordae) (2010)</li> <li>- Edwards Lifesciences : Valves (2011)</li> <li>- Medtronic : valves (2011)</li> <li>- Valtech : Valves (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : heart valves (2010)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- St Jude Medical : heart valves (2010)</li> <li>D - Research funding (departmental or institutional).</li> <li>- Edwards Lifesciences : heart valves, rings (2010)</li> <li>- Philips : Imaging (2011)</li> </ul>
lung Bernard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : benfluorex (2010-2011)</li> <li>- Boehringer-Ingelheim : dabigatran (2010-2011)</li> <li>- Edwards Lifesciences : heart valve prosthesis (2010-2011)</li> <li>- St Jude Medical : heart valve prosthesis (2010)</li> <li>- Abbott : Mitraclip (2010-2011)</li> <li>- Sanofi Aventis : None (educational program) (2010-2011)</li> <li>- Bayer : rivaroxaban (2010-2011)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Heart Failure (2011)</li> <li>- ,astra zeneca, boheringer, menarini : pradaxa, belsar, crestor (2010)</li> <li>- Bayer Healthcare : Xarelto (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : tracleer (2010)</li> <li>- Servier : Coversyl (2011)</li> <li>- Astra Zeneca : Crestor (2011)</li> </ul>
Pierard Luc	<ul style="list-style-type: none"> <li>- Novartis : Aliskiren (2011)</li> <li>- Astra Zeneca : Rosuvastatin Ticagrelor (2011)</li> <li>- General Electric : VIVID 9 (2011)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Aliskiren (2010)</li> <li>- Merck Sharp &amp; Dohme : Ezetimibe (2010)</li> <li>- General Electric : No (2010)</li> <li>- Astra Zeneca : Rosuvastatine (2010)</li> <li>- Astra Zeneca : Rosuvastatine (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Rosuvastatine (2010)</li> </ul>
Price Susanna	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Consultant (2010-2011)</li> <li>- Medtronic : Honoraria for educational lectures (1-2 per annum) (2010-2011)</li> </ul>
Schaefers Hans-Joachim	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : DSMB, speaker (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : speaker (2010)</li> <li>- Edwards Lifesciences : speaker (2011)</li> <li>- St Jude Medical : speaker (2011)</li> </ul>
Schuler Gerhard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Percutaneous Valves (2010-2011)</li> <li>- Boston Scientific : Watchman Device (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Stents (2010)</li> <li>- Medtronic : Stents (2011)</li> </ul>
Stepinska Janina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation (2011)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation (2010)</li> <li>- Bristol Myers Squibb : anticoagulation (2011)</li> <li>- Bristol Myers Squibb : anticoagulation (2010)</li> <li>- Egis Pharma : anticoagulation (2010)</li> <li>- Eli Lilly : anticoagulation/prasugrel (2010)</li> <li>- Bayer Healthcare : anticoagulation/rivaroxaban (2010-2011)</li> <li>- Astra Zeneca : anticoagulation/ticagrelor (2010)</li> <li>- Sanofi Aventis : antiplatelet, antiarrhythmic (2010)</li> <li>- Astra Zeneca : antiplatelet/ticagrelor (2011)</li> <li>- Merck Sharp &amp; Dohme : lipid lowering therapy (2010)</li> <li>- Servier : registry, NC (2010)</li> <li>- Astra Zeneca : ACS, registry (2011)</li> <li>- Cothera : acute heart failure/relaxin (2011)</li> <li>- Bayer : atrial fibrillation, registry (2011)</li> <li>- Sanofi Aventis : dronedaron (2011)</li> <li>- Servier : stable angina, registry (2011)</li> <li>- Trevena : TRV120027, stable heart failure (2011)</li> </ul>
Swedberg Karl	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : candesartan (2010)</li> <li>- Amgen : Heart failure (2011)</li> <li>- Novartis : Heart failure (2011)</li> <li>- Servier : ivabradine (2011)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen Inc : darbepoetin (2010)</li> <li>- Amgen Inc : darbepoetin (2011)</li> <li>- Servier : heart failure (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novartis, Astra-Zeneca, Menarini, Bayer, Takeda, Daiichi-Sankyo, Otsuka, Servier : several (2010)</li> <li>- Amgen : heart failure (2011)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Amgen : darbepoetin (2010)</li> </ul>
Takkenberg Jjm	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cryolife : human tissue valves (2010)</li> <li>- Sorin Group : prosthetic valves (2010)</li> <li>- Cryolife : human tissue valves (2011)</li> <li>- Sorin Group : prosthetic valves (2011)</li> </ul>
Vahanian Alec	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : valve disease (2011)</li> <li>- Valtech : valve disease (2011)</li> <li>- Medtronic Foundation : valve disease (2011)</li> <li>- saint Jude medical : valve disease (2011)</li> <li>- Edwards Life sciences : valve disease (2011)</li> <li>- Abbott : Valve prostheses (2010)</li> <li>- Boehringer-Ingelheim : Valve prostheses (2010)</li> <li>- Edwards Lifesciences : Valve prostheses (2010)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Medtronic : Valve prostheses (2010)</li> <li>- Valtech : Valve prostheses (2010)</li> <li>- Siemens Healthcare : Valve prostheses (2010)</li> </ul>
von Oppell Ulrich	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Aortic &amp; Mitral Valve surgery (2010-2011)</li> <li>- Vascutek Ltd : Aortic grafts (2010)</li> <li>- Vascutek Ltd : Aortic Valve repair and Aortic grafts (2011)</li> <li>- Medtronic : Mitral Valve Repair &amp; Atrial fibrillation surgery (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Aortic valve trial (2010)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug (2010-2011)</li> <li>- Eli Lilly : Antiplatelet drug (2010-2011)</li> <li>- Abbott : Stent (2010-2011)</li> <li>- Biosensors : Stent (2010-2011)</li> <li>- Boston Scientific : Stent (2010-2011)</li> <li>- Medtronic : Stent (2010-2011)</li> <li>- Biotronik : Stent (2010-2011)</li> <li>- Cordis : Stent (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Stent (2010)</li> <li>- Biosensors : Stent (2010)</li> <li>- Medtronic : Stent (2010)</li> <li>- Cordis : Stent (2010)</li> </ul>



## Guidelines on Valvular Heart Disease (TF29) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- St Jude Medical : OCT (2011)</li> <li>- Abbott : Stent (2011)</li> <li>- Biosensors : Stent (2011)</li> <li>- Medtronic : Stent (2011)</li> <li>- Biotronik : Stent (2011)</li> <li>- Cordis : Stent (2011)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation (2010)</li> <li>- Philips : Imaging (2010)</li> <li>- Merck Sharp &amp; Dohme : Lipids (2010)</li> <li>- Abbott Vascular : IMAGING IN HF (2011)</li> <li>- Merck Sharp &amp; Dohme : LIPIDS (2011)</li> </ul>
Zembala Marian	None

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

## Guidelines on Valvular Heart Disease (TF29) - Document Reviewers

Expert	Type of Relationship with Industry
Badano Luigi Paolo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Malesci : Hypertension, hypercholesterolemia (2010)</li> <li>- Medtronic : Medical devices (2010)</li> <li>- GE Healthcare : Medical devices (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- GE Healthcare : medical devices (2010)</li> </ul>
Bunc Matjaz	None
Claeys Marc	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medicines Company : bivalirudine (2010-2011)</li> <li>- Eli Lilly : prasugrel, abciximab (2010-2011)</li> <li>- Abbott Vascular : stents (2010)</li> <li>- Abbott Vascular : stents- mitraclip (2011)</li> <li>- Astra Zeneca : ticagrelor (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : coronary stent and corevalve (2010)</li> <li>- Medtronic : coronary stent and corevalve (2011)</li> </ul>
Drinkovic Niksa	None
Filippatos Gerasimos	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Torrent : Heart failure (2010)</li> <li>- Vifor International : Heart failure (2010)</li> <li>- Corthera, Novartis : Heart failure (2010)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - Document Reviewers

Expert	Type of Relationship with Industry
	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- BRAHMS GmbH : Biomarkers (2010)</li> <li>- Roche Pharma : Biomarkers (2010)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Nanosphere : Biomarkers (2010)</li> <li>- European Union : Heart failure (2010)</li> </ul>
Habib Gilbert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : heart failure (2010)</li> <li>- Pfizer : pulmonary hypertension (2010-2011)</li> <li>- Actelion : pulmonary hypertension (2010-2011)</li> <li>- Lilly : pulmonary hypertension (2010)</li> </ul>
Kappetein A Pieter	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Transcatheter heart valve (steering committee member) (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Atricure : atrial fibrillation (2011)</li> <li>- Boston Scientific : Coronary stenosis (2011)</li> <li>- Abbott Vascular : Coronary stenosis (2011)</li> <li>- Edwards Lifesciences : Valves (2011)</li> <li>- Medtronic : Valves (2011)</li> <li>- Abbott Vascular : Valves (2011)</li> </ul>
Kassab Roland Youssef	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : New Oral Anticoagulation (2011)</li> <li>- Astra Zeneca : Speaker fees, Advisory board fees, from several companies (2010)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - Document Reviewers

Expert	Type of Relationship with Industry
Lip Gregory Yh	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biotronik : atrial fibrillation (2010-2011)</li> <li>- Portola Pharmaceuticals : atrial fibrillation (2010)</li> <li>- Merck Sharp &amp; Dohme : atrial fibrillation (2010)</li> <li>- BMS : atrial fibrillation, thrombosis (2010-2011)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2010-2011)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2010-2011)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2011)</li> <li>- Astellas : atrial fibrillation, thrombosis (2011)</li> <li>- Astellas : atrial fibrillation, thrombosis (2010)</li> <li>- Bayer Schering Pharma : atrial fibrillation, thrombosis (2010)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis [sums from each] (2010)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2010)</li> <li>- Bayer Schering Pharma : atrial fibrillation, thrombosis (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2010)</li> <li>- Bayer : atrial fibrillation, thrombosis (2011)</li> </ul>
Moat Neil	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CoreValve (2010)</li> <li>- Medtronic : CoreValve (2011)</li> <li>- Abbott Vascular : Mitraclip (2010)</li> <li>- Edwards Lifesciences : Physio annuloplasty systems (2010)</li> <li>- Abbott Vascular : Mitraclip (2011)</li> </ul>

## Guidelines on Valvular Heart Disease (TF29) - Document Reviewers

Expert	Type of Relationship with Industry
Nickenig Georg	None
Otto Catherine M	C - Receipt of royalties for intellectual property. - Elsevier : Medical textbooks (2010) - Up to Date : Online medical informaton (2010)
Pepper John	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Covidien : Near infra-red spectroscopy (2010)
Piazza Nicolo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Transcatheter Aortic Valve (2010-2011) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - CardiaAQ : Transcatheter Mitral Valve (2010) - CardiaAQ : Transcatheter Mitral Valve (2011)
Pieper Els Petronella G	D - Research funding (departmental or institutional). - Sorin Group : funding for research on prosthetic heart valves in congenital heart disease (prostava study); total amount 50.000 euro; Main funding of this project is by Netherlands Heart Foundation. Funders have had no saying in the design of the study and will not be involved in the scientific output arising from this study (2010) - Sorin Group : funding for research on prosthetic heart valves in congenital heart disease (prostava study); total amount 50.000 euro; Main funding of this project is by Netherlands Heart Foundation. Funders have had no saying in the design of the study and will not be involved in the scientific output arising from this study (2011)
Popescu Bogdan Alexandru	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging (2010-2011)
Rosenhek Raphael	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Edwards Lifesciences : Valvular heart disease (2010) - Edwards Lifesciences : Valvular heart disease (2011)

## Guidelines on Valvular Heart Disease (TF29) - Document Reviewers

Expert	Type of Relationship with Industry
Schwammenthal Ehud	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Consultant to Medtronic Ventor (transcatheter valve products, cardiovascular devices) (2010-2011)
Schwitter Juerg	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Xarelto (2010) - Bayer : Xarelto (2011)  D - Research funding (departmental or institutional). - Bayer : not applicable (2010) - Medtronic : not applicable (2010) - Bayer : not applicable (2011) - Medtronic : not applicable (2011) - Bracco Pharmaceutical : not applicable (2011)
Shuka Naltin	None
Tornos Mas Pilar	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Consultancu (2011) - Boehringer-Ingelheim : dabigatran Speaker fees (2010) - Servier : ivabradine Speker fees (2010) - Abbott : Mitral clip. Consultancy (2011) - Bayer : Speaker fees (2011) - Boehringer-Ingelheim : Speaker fees (2011) - Edwards Lifesciences : speaker fees mitral valve repair meeting (2010)
Trigo Trindade Pedro	None
von Segesser Ludwig K	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.

## Guidelines on Valvular Heart Disease (TF29) - Document Reviewers

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Symetis SA : Catheter valves (2010-2011)</li> <li>- Swiss Heart Foundation : Promotê information, education and resaerch in the cardio-vascular field (2010-2011)</li> <li>- Smartcanula LLC : Self-expanding cannulas (2010-2011)</li> </ul>
Walther Thomas	<ul style="list-style-type: none"> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Edwards Lifesciences : Transcatheter heart valve (2010)</li> </ul>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2010-2011)</li> <li>- AGA : Devices for catheter treatment of congenital heart defects (2010)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter valve implantation (2010)</li> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2011)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2011)</li> </ul>
Bax Jeroen	<ul style="list-style-type: none"> <li>- Heart.org : Education (2010)</li> <li>- Astra Zeneca : Farma (2010)</li> <li>- Servier : Farma (2010)</li> <li>- Philips : Imaging (2010)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Lantheus Inc : Imaging (2010)</li> <li>- Boston Scientific : Pacing (2010)</li> <li>- Medtronic : Pacing (2010)</li> <li>- St Jude Medical : Pacing (2010)</li> <li>- Biotronik : Pacing (2010)</li> <li>- Impulse Dynamics : Pacing (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2010)</li> <li>- Edwards Lifesciences : Heart Valves (2010)</li> <li>- GE Healthcare : Imaging (2010)</li> <li>- Lantheus Inc : Imaging (2010)</li> <li>- Boston Scientific : Pacing (2010)</li> <li>- Medtronic : Pacing (2010)</li> <li>- St Jude Medical : Pacing (2010)</li> <li>- Biotronik : Pacing (2010)</li> <li>- Servier : Farma (2011)</li> <li>- Edwards Lifesciences : Heart Valves (2011)</li> <li>- GE Healthcare : Imaging (2011)</li> <li>- Lantheus Inc : Imaging (2011)</li> <li>- Boston Scientific : Pacing (2011)</li> </ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Medtronic : Pacing (2011)</li> <li>- St Jude Medical : Pacing (2011)</li> <li>- Biotronik : Pacing (2011)</li> </ul>
Ceconi Claudio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Pharmaceutical (2010-2011)
Deaton M Christi	<ul style="list-style-type: none"> <li>- St Jude Medical : Cath lab - speaker X 1 (2010)</li> <li>- Daiichi Sankyo : consultant for patient adherence 2009-10 (2010)</li> <li>- Eli Lilly : consultant for patient adherence 2009-10 (2010)</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Novo-Nordisk : medicines for diabetes (2010)</li> <li>- Novo-Nordisk : patients with heart failure and diabetes (2011)</li> </ul>
Fagard Robert	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Honorarium for manuscript (2011) - Servier : Honorarium for manuscript in Medicographia (2010)
Funck-Brentano Christian	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Novartis CH : Adjudication Committee on an immunosuppressant (2011)</li> <li>- Lundbeck : Cardiac safety of an antidepressant (2011)</li> <li>- Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2010-2011)</li> <li>- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2010-2011)</li> <li>- Johnson &amp; Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials.</li> <li>- MMV (CH) : Cardiac Safety of an antimalarial drug (2010-2011)</li> <li>- Santhera (CH) : Cardiac Safety of an antimalarial drug (2010-2011)</li> <li>- Sigma Tau : Cardiac Safety of an antimalarial drug (2010-2011)</li> <li>- TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2010-2011)</li> <li>- CEPHALON : DSMB in an oncology phase IIb trial (2010-2011)</li> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2010-2011)</li> <li>- Intracellular Therapies USA : Psychotropic drug development (2011)</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel (2010)</li> </ul>
Hasdai David	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Sanofi Aventis : Enoxaparin (2010)</li> <li>- Boehringer-Ingelheim : Pradaxa (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Bayer : Rivaroxiban (2011)</li> <li>- Astra Zeneca : Ticagrelor (2011)</li> <li>- Eli Lilly : Effient (2011)</li> </ul>
Hoes Arno	<ul style="list-style-type: none"> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips</li> <li>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010)</li> <li>- Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010)</li> <li>- Roche Pharma : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome (2010)</li> </ul> </li> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2011)</li> </ul>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : cardiovascular (2011)</li> <li>- Boehringer-Ingelheim : cardiovascular (2011)</li> <li>- Daiichi Sankyo : cardiovascular (2011)</li> <li>- Medtronic : cardiovascular (2011)</li> <li>- St Jude Medical : cardiovascular (2011)</li> <li>- Sanofi Aventis : cardiovascular (2011)</li> <li>- Meda pharma : cardiovascular (2011)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2011)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2011)</li> <li>- Sanofi Aventis : cardiovascular (2011)</li> <li>- Meda pharma : cardiovascular (2011)</li> </ul>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : Imaging tracers (2010)</li> <li>- Lantheus Inc : Perfusion imaging tracer development (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Development of imaging agents (2010)</li> <li>- Novartis : Development of imaging agents (2010)</li> <li>- GE Healthcare : Development of imaging agents (2010)</li> <li>- Lantheus Inc : Development of imaging agents (2010)</li> <li>- Roche Pharma : Drugs for brain diseases (2010)</li> <li>- Astra Zeneca : Neurology (2011)</li> <li>- GE Healthcare : Neurology and molecular imaging (2011)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic agents (2010)</li> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic agents (2011)</li> <li>- Astra Zeneca : Antiplatelet agents (2010-2011)</li> <li>- Bristol Myers Squibb : Antiplatelet agents (2010)</li> <li>- Regado Biosciences : Antithrombotic agents (2010-2011)</li> <li>- Abbott : coronary stents (2010)</li> <li>- Abbott Vascular : Coronary stents (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2010)</li> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves (2010)</li> <li>- Medtronic : Cardiac valves (2010)</li> <li>- St Jude Medical : Cardiac valves (2010)</li> <li>- Siemens Healthcare : Imaging (2010)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2010)</li> <li>- Edwards Lifesciences : Cardiac valves (2011)</li> <li>- Medtronic : Cardiac valves (2011)</li> <li>- St Jude Medical : Cardiac valves (2011)</li> <li>- Boston Scientific : Coronary stents (2011)</li> <li>- Siemens Healthcare : Medical imaging (2011)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
McDonagh Theresa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Vifor International : Ferrinject (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : Ivabridine (2010)            - Servier : Ivabridine (2011)</p> <p>D - Research funding (departmental or institutional).            - Biotronik : CRT (2010)</p>
Popescu Bogdan Alexandru	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - GE Healthcare : Imaging (2010-2011)</p>
Reiner Zeljko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Bayer : anticoagulants (2011)            - Bayer Healthcare : anticoagulants (2010)            - Abbott : antilipemics (2010)            - Astra Zeneca : antilipemics (2010-2011)            - Pfizer : antilipemics (2010-2011)            - Sanofi Aventis : antilipemics (2011)            - Abbott Laboratories : antilipemics (2011)            - Merck Sharp &amp; Dohme : antilipemics (2010)            - Merck Sharp &amp; Dohme : antilipemics (2011)</p>
Sechtem Udo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Boehringer-Ingelheim : Anticoagulation (2010-2011)            - Daiichi Sankyo : Antiplatelet therapy (2010)            - Novartis : Drugs (2010-2011)            - Pfizer : Drugs (2011)            - Siemens Healthcare : Imaging (2010)            - General Electric : Imaging (2010)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Novartis : Imaging devices (2010)            - Johnson &amp; Johnson : Stents (2010)            - Novartis : Drugs (2011)            - Johnson &amp; Johnson : Stents (2011)</p>
Sirnes Per Anton	

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010)</li> <li>- Merck Sharp &amp; Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010)</li> <li>- GlaxoSmithKline : investigator fee, clinical study , SCAD (2010)</li> <li>- Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010)</li> <li>- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010)</li> <li>- Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010)</li> <li>- Boehringer-Ingelheim : investigator fee, clinical study, AF (RELY. RELYABLE) (2010)</li> <li>- Merck Sharp &amp; Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011)</li> <li>- GlaxoSmithKline : investigator fee, clinical study , SCAD (2011)</li> <li>- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011)</li> <li>- Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)</li> </ul>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2011)</li> <li>- Amgen : Darbopietin (2011)</li> <li>- Servier : Ivabradine, Phase II investigational products (2011)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2011)</li> <li>- TIMI group : Rivaroxaban (2011)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation (2010)</li> <li>- Sanofi Aventis : anticoagulation (2010)</li> <li>- Pfizer : anticoagulation, pulmonary hypertension (2010)</li> <li>- United Therapeutics : Pulmonary arterial hypertension (2011)</li> <li>- GSK : pulmonary arterial hypertension - ambrisentan (2011)</li> <li>- Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011)</li> <li>- Lilly : pulmonary arterial hypertension - tadalafil (2011)</li> <li>- AOP : Pulmonary arterial hypertension - treprostinil (2011)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat (2011)</li> <li>- Actelion : pulmonary hypertension (2010)</li> <li>- Lilly : pulmonary hypertension (2010)</li> <li>- Bayer Healthcare : pulmonary hypertension, anticoagulation (2010)</li> <li>- Bristol Myers Squibb : thromboembolic disease - Apixaban (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	<ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2011)</li> <li>- Sanofi Aventis : Thromboembolic disease (2011)</li> </ul>
Vahanian Alec	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : valve disease (2011)</li> <li>- Valtech : valve disease (2011)</li> <li>- Medtronic Foundation : valve disease (2011)</li> <li>- saint Jude medical : valve disease (2011)</li> <li>- Edwards Life sciences : valve disease (2011)</li> <li>- Abbott : Valve prostheses (2010)</li> <li>- Boehringer-Ingelheim : Valve prostheses (2010)</li> <li>- Edwards Lifesciences : Valve prostheses (2010)</li> <li>- Medtronic : Valve prostheses (2010)</li> <li>- Valtech : Valve prostheses (2010)</li> <li>- Siemens Healthcare : Valve prostheses (2010)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug (2010-2011)</li> <li>- Eli Lilly : Antiplatelet drug (2010-2011)</li> <li>- Abbott : Stent (2010-2011)</li> <li>- Biosensors : Stent (2010-2011)</li> <li>- Boston Scientific : Stent (2010-2011)</li> <li>- Medtronic : Stent (2010-2011)</li> <li>- Biotronik : Stent (2010-2011)</li> <li>- Cordis : Stent (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Stent (2010)</li> <li>- Biosensors : Stent (2010)</li> <li>- Medtronic : Stent (2010)</li> <li>- Cordis : Stent (2010)</li> <li>- St Jude Medical : OCT (2011)</li> <li>- Abbott : Stent (2011)</li> <li>- Biosensors : Stent (2011)</li> <li>- Medtronic : Stent (2011)</li> <li>- Biotronik : Stent (2011)</li> </ul>

## ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
	- Cordis : Stent (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.